1.37
Schlusskurs vom Vortag:
$1.39
Offen:
$1.43
24-Stunden-Volumen:
6.12M
Relative Volume:
0.85
Marktkapitalisierung:
$413.74M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-0.9133
EPS:
-1.5
Netto-Cashflow:
$-260.90M
1W Leistung:
-9.87%
1M Leistung:
-24.31%
6M Leistung:
+12.30%
1J Leistung:
-1.44%
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
PACB
Pacific Biosciences Of California Inc
|
1.37 | 419.78M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
110.55 | 195.75B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
358.65 | 140.03B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
89.89 | 117.27B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.96 | 106.69B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.78 | 48.94B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Why The PacBio (PACB) Investment Story Is Shifting As Analysts Cut Targets And Flag Risks - Yahoo Finance
HiFi sequencing enables automatic detection of 5mC and 6mA, Pacific Biosciences of California asserts - Traders Union
Pacific Biosciences Secures Key Patent License, Ends Litigation - TipRanks
Pacific Biosciences announces accounting officer transition and litigation settlement - Investing.com
PACB - Finviz
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Finviz
PACB Analyst Rating Downgrade by Barclays to Underweight | PACB Stock News - GuruFocus
Pacific Biosciences of California (NASDAQ:PACB) Receives Underweight Rating from Barclays - MarketBeat
Barclays downgrades Pacific Biosciences stock rating on catalysts By Investing.com - Investing.com Canada
Barclays downgrades Pacific Biosciences stock rating on catalysts - Investing.com UK
PacBio Announces the Appointment of Chris Gibson to the Board of Directors - Sahm
Pacific Biosciences of California unveils HiFi sequencing for comprehensive multiomic analysis - Traders Union
PacbBio Announces Appointment of Christopher Gibson to Board of Directors and Member of the Science and Technology Committee, Effective March 3, 2026 - marketscreener.com
PacBio Adds AI-Driven Drug Discovery Leader to Board - TipRanks
Pacbio announces the appointment of Chris Gibson to the board of directors - marketscreener.com
PacBio Appoints New Board Member - Intellectia AI
AI drug discovery founder from Recursion joins PacBio board - Stock Titan
Pacific Biosciences of California, Inc. $PACB Shares Sold by ARK Investment Management LLC - MarketBeat
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 By Investing.com - Investing.com Canada
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 - Investing.com Australia
Pacific Biosciences of California (NASDAQ:PACB) Insider Christian Henry Sells 12,497 Shares - MarketBeat
PRISM 2026 set to shape genomics future, Pacific Biosciences of California asserts - Traders Union
PACB,TAL Volatility & Greeks - Finviz
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - Finviz
Intuitive Surgical Expands Direct Operational Presence in Europe - Finviz
Life Sciences Tools & Services Stocks Q4 Recap: Benchmarking PacBio (NASDAQ:PACB) - Yahoo Finance
Equity awards to Pacific Biosciences (PACB) officer disclosed - Stock Titan
PACB (PACB) grants James R. Gibson II 667,696 options and 333,848 RSUs - Stock Titan
Pacific Biosciences (PACB) officer receives large option and RSU awards - Stock Titan
Large equity grants to PacBio (PACB) executive highlight retention focus - Stock Titan
Christian Henry sells 472,667 PACB shares (PACB) on Form 144 - Stock Titan
PacBio and DNAstack Join Forces to Launch Worldwide HiFi Genome Network Hub - Bitget
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub - Yahoo Finance
Pacific Biosciences of California enables automatic epigenetic data in HiFi sequencing runs - Traders Union
Pacific Biosciences of California backs San Diego event to strengthen rare disease awareness - Traders Union
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Finviz
PACB,TAL Revenue Breakdown - Finviz
Pacific Biosciences of California joins IRDiRC to advance rare disease research - Traders Union
Vestmark Advisory Solutions Inc. Sells 692,663 Shares of Pacific Biosciences of California, Inc. $PACB - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pacific Biosciences of California (PACB) Stock Analysis: A 53% Upside Awaits in the Genomic Sequencing Arena - DirectorsTalk Interviews
Pacific Biosciences Of California Files For Mixed Shelf Size - TradingView
[10-K] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files Annual Report | PACB SEC FilingForm 10-K - Stock Titan
Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance
PacBio (PACB) Joins Forces with DNAstack for Global Genomic Data Collaboration - GuruFocus
Volume Recap: Is Pacific Biosciences of California Inc stock a buy or sell2025 Winners & Losers & Free Reliable Trade Execution Plans - baoquankhu1.vn
PacBio and DNAstack launch first global federated HiFi whole genome dataset to accelerate rare disease research - marketscreener.com
Global genome network to speed answers for rare disease patients - Stock Titan
Pacific Biosciences of California examines technology impact on DNA sequencing insights - Traders Union
Pacific Biosciences COO Sells Shares - Intellectia AI
Why The PacBio (PACB) Narrative Is Shifting Around Fair Value And Long Read Sequencing - Yahoo Finance
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):